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We present a patient who developed the Lambert-Eaton myasthenic syn- 
drome (LEMS) in association with systemic lupus erythematosus (SLE). 
Severe proximal weakness with electrodiagnostic evidence of LEMS devel- 
oped over 2 days during an exacerbation of cutaneous manifestations (bul- 
lous pemphigoid) associated with SLE. Following an increase in the daily 
dose of prednisone, there was complete clinical restitution of strength within 
2 weeks and a slower resolution of electrodiagnostic abnormalities over 6 
months. Marked serologic abnormalities were present at the onset and 
showed improvement over 6-8 months. LEMS had been infrequently de- 
scribed in association with SLE. The immunologic features of both SLE and 
LEMS suggest a linkage between the two diseases in this patient. We hy- 
pothesize that increased antibodies associated with exacerbation of SLE 
cross reacted with the neuromuscular junction membrane to produce 
LEMS. 
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TRANSIENT LAMBERT-EATON 
MYASTHENIC SYNDROME 
ASSOCIATED WlTH SYSTEMIC LUPUS 
ERYTHEMATOSUS 
MARK B. BROMBERG, MD, PhD, JAMES W. ALBERS, MD, PhD. 
and W. JOSEPH McCUNE, MD 
There  is growing evidence that the Lambert- 
Eaton myasthenic syndrome (LEMS)4,13 is an au- 
toimmune disease. l4 Passive transfer of the disor- 
der has been demonstrated in suitably prepared 
mice by injection of the IgG component of serum 
from affected  patient^."""^"^ Transfer is not re- 
lated to the presence of an underlying tumor.I4 
The antigenic target is unknown, but protein com- 
plexes in the active zone of the presynaptic mem- 
brane, possibly associated with calcium channels, 
have been hypothesized5 Patients with LEMS, 
with or without neoplasm, have shown improve- 
ment with immunosuppressive therapies, includ- 
ing combinations of prednisone and azothioprine, 
and with therapeutic plasma e x ~ h a n g e . ~ ' , ~ ~ , ' ~  In 
addition to neoplasms, LEMS has also been associ- 
ated with autoimmune disorders."." There is a 
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higher-than-expected association of organ-specific 
autoantibodies (antithyroid, antiparietal cell, anti- 
acctylcholine receptor) than non-organ-specific 
autoantibodies (K heumatoid factor, antinuclear 
antibody) in patients with LEMS. " Consequently, 
IAF,MS is more frequently associated with thyroidi- 
tis and pernicious anemia than with SLE, Sjogrens 
syndrome, rheumatoid arthritis, or progressive 
systemic sclerosis, and only one case of LEMS has 
been reported in a patient with Sl,E.8 Of note, 
myasthenia gravis is common to both organ- 
specific and non-organ-specific groups, and there 
are reports of electrophysiologic findings of both 
myasthenia gravis and LEMS in the same 
patient." 
The clinical picture of LEMS is chronic pro- 
grcssive weakness, measured over months to 
years, involving proximal muscles more than distal 
muscles, but usually sparing bulbar muscles.2" 
The usual therapeutic response to immunosup- 
pression is slow, with objective clinical improve- 
rricnt commencing from 14 days to 3 months after 
initiation of t h ~ r a p y . ~ ~  We present a patient with 
transient symptoms and signs of LEMS occurring 
concomitantly with an exacerbation of SLE. The 
association of these two conditions suggests that 
the transient LEMS may have been a component 
of a more generalized autoimmune disorder, 
likely related to either formation of multiple au- 
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FIGURE 1. Temporal relationship between strength (MRC scale, 5 = normal; upper graph), prednisone dosage (middle graph), and 
other medications (lower graph). 
toantibodies with different specificities or au- 
toantibodies capable of cross reacting with differ- 
ent antigens. 
CASE PRESENTATION 
The patient was a 21-year-old black female with 
SLE for 5 years. She fulfilled 8 of 11 ARA criteria 
for SLEZ5 (Table l) ,  and her disease was charac- 
terized by discoid lupus and bullous peniphigoid 
lesions. She had no known previous central or pe- 
ripheral nervous system involvement. During the 
4-6 weeks prior to onset of weakness, she was 
treated with Nafcillin, Tobramycin, and Doxicycil- 
lin for minor toe and scalp infections (Fig. 1). Five 
weeks prior to onset of weakness she was placed 
on hydroxychloroquine (200 mg qD) for 1 month 
for a flare of her bullous phemphigoid. Because 
of continuing skin eruptions and pruritus, hy- 
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droxychloroquine was discontinued and a burst of 
prednisone was instituted, starting at 40 mg qD 
and tapering to zero over 10 days. At the end of 
the burst, prednisone was restarted at 40 mg qD 
because of persistent skin lesions. Her weakness 
began 1 week later with marked proximal weak- 
ness progressing over 2 days. She was unable to el- 
evate her arms against gravity, rise from bed, or 
walk without assistance. Muscle stretch reflexes, 
originally normal, became hypoactive and then ab- 
sent. Pupillary function was normal, and there 
were no other signs of cholinergic blockade. At 
onset of weakness, prednisone was increased to 60 
mg qD and maintained for several months. She 
experienced an improvement in strength within 4 
days of dose change and was clinically normal 
within 2 weeks. She has remained strong without 
evidence of a neoplasm after 48 months of follow- 
UP. 
Electrodiagnostic studies were performed seri- 
ally after onset of weakness (Table 2). During 
maximum weakness all compound muscle action 
potential (CMAP) amplitudes were reduced. 
There was up to a 30% decrement at low fre- 
quency repetitive stimulation (2 Hz supramaximal 
stimulation; Fig. 2A) and up to 300% facilitation 
at high frequency stimulation (50 Hz supramaxi- 
ma1 stimulation; Fig. 2B) or immediately after 5 
seconds of maximal voluntary exercise (Fig. 2A). 
All electrodiagnostic abnormalities resolved over 6 
months (Fig. 3) with restoration of CMAP ampli- 
tude and decreased decrement and facilitation to 
normal values (Fig. 2C). 
At the time of maximum weakness, serum po- 
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Table 2. Sensory and motor nerve evoked responses 
Date 
Test 212 1 312 611 4 8/23 Normal values 
Sural nerve 
Ulnar motor nerve 
Decrement at 2Hz (%) 30 25 10 0 None 
Facilitation with exercise (%) 300 300 50 30 <50 
Distal latency (msec) 3.2 2.6 2.6 2.7 1.8-3.5 
Extensor digitorum communis muscle jitter (psec) NA NA NA 41 16-33 
Amplitude (pV) 20 NA NA 20 >6 
Amplitude (mV) 2.0 1.8 7.0 8.0 6-16 
Single fiber EMG 
Note: NA = not available. 
tassium, magnesium, calcium, and thyroid func- 
tion tests were normal. Antiacetylcholine receptor 
autoantibody titers were undetectable. The hema- 
tocrit was 28.8 with microcytic indices. Total he- 
molytic complement, C3, and C4 were depressed 
(Table 3). The Raji Cell assay, ANA, and anti- 
DNA (Farr assay) were elevated. Immunofluores- 
cent staining of a skin biopsy showed positive 
ANA deposition. Over the next 6 months the 
complement and autoantibodies abnormalities im- 
proved (Table 3). 
DISCUSSION 
This patient fulfilled the clinical and electrodiag- 
nostic criteria for LEMS; proximal weakness spar- 
ing bulbar muscles, low CMAP amplitude, decre- 
mental response at low stimulus rates, and 
abnormal facilitation at high stimulation rates or 
after e x e r ~ i s e . ~  Her clinical course is unique, with 
subacute onset and rapid resolution of weakness. 
There were no serum electrolyte abnormalities as- 
sociated with the weakness and no evidence for 
myasthenia gravis. A pharmacologically induced 
neuromuscular transmission defect was unlikely. 
There was no evidence that unintended medica- 
tions were administered. Chloroquine, an ana- 
logue of hydroxychloroquine, has been associated 
with postoperative respiratory depression, and 
there is evidence that it acts postsynaptically. 
Less is known about hydroxychloroquine. Our pa- 
tient received no hydroxychloroquine during the 
2 weeks prior to onset of weakness. After inges- 
tion, the clinical half-life of hydroxychloroquine is 
50-56 hours, with the majority excreted with a 
half-life of 3 days while the remainder of the drug 
is excreted more slowly." Additionally, our pa- 
tient had taken hydroxychloroquine at an earlier 
time and has been on chloroquine since, without 
weakness. She also had taken a 2 day course of an 
aminoglycoside antibiotic, Tobramycin, 2 months 
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FIGURE 2. Compound muscle action potentials (recorded from hypothenar muscles) to repetitive supramaximal ulnar nerve stimulation 
during maximal weakness (A and B) and after clinical remission (C). (A) 2 Hz stimulation before (lower traces) and immediately after 
(upper traces) 5 seconds of maximal voluntary contraction. (B) 50 Hz stimulation. (C) 2 Hz stimulation before (left traces), immediately 
after (middle traces), and 30 seconds after (right traces) 5 seconds of maximal voluntary contraction. 
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FIGURE 3. Temporal relationship of results of ulnar nerve stimulation (recorded from hypothenar muscles), demonstrating compound 
muscle action potential amplitude (a), maximal percentage decrement to 2 Hz repetitive stimulation (A), and percentage facilitation 
immediately after 5 seconds of maximal voluntary contraction (m). 
prior to onset of weakness. Aminoglycosides affect 
neuromuscular transmission both pre- and post- 
~ynapt ical ly ,~~ but Tobramycin is least toxic3 
Weakness has been associated with the institution 
of prednisone in patients with myasthenia gravis. 
The effects of prednisone on neuroniuscular jun(-- 
tion transmission have been studied, and both pr- 
esynaptic and postsynaptic actions have been derri- 
onstrated in neurornuscular junction prepara- 
tions.28 It is not known if these effects can be ex- 
trapolated to pharmacologic doses and clinical sit - 
uations. In addition to direct action at the neuro- 
muscular junction, an indirect effect has been 
postulated, based on varying degrees of suppres- 
sion of different lymphocyte subsets at onset of 
prednisone Transient increase in 
weakness has not been noted in LEMS in associa- 




2/84 8/84 values 
Total complement 24 59 104-188 units 
C l q  (Raji 659 NA 0-49 AHG eqiML* 
c3 40 56 80-231 mg% 
c 4  5 10 10-46mg% 
ANA 1 :2560 NA <1:80 
(speckled pattern) 
Anti-DNA 69 23 0- 25% 
cell assay) 
(Farr assay) 
Note. NA = not availabie 
'Aggregated human gamma globulin equivalents 
tion with institution of prednisone. Our patient 
had been on prednisone prior to and since her 
transient weakness, and in doses up to 120 mg qD, 
without associated weakness. 
'The antigenic spectrum of SLE is broad. Cross 
reactivity of autoantibodies in SLE has been dem- 
onstrated on a monoclonal level. Hybridomas pro- 
ducing monoclonal antibodies reacting to dena- 
tured DNA were derived from lymphocytes of 
patients with SLE. Eighteen of 30 antibody lines 
reacted with denatured DNA and three or more 
additional polynucleotides. Ten of the 30 lines re- 
acted with nucleic acids and phospholipid cardio- 
lipin." In addition to activity directed to cell nu- 
cleus antigens, there is evidence for antibody ac- 
tivity against neuronal antigens. Sera from 75% of 
patients with SLE have been shown to bind with 
either cultured neuronal cell lines or human brain 
tissue. An association between antineuronal anti- 
gen binding and neuropsychiatric symptoms in 
SLE is an inconsistent finding.' 
Our patient had supplementary immunologic 
evidence for a severe exacerbation of SLE. Com- 
plement levels (total complement, C3, C4) were 
low and were partially restored over 6-8 months 
(Table 1). Skin biopsy at time of weakness showed 
linear deposition of all immunoglobulin classes. 
The time course of onset and resolution of 
weakness in our patient was unusually short. In 
the passive humoral transfer animal model of 
LEMS, where the time course can be documented, 
animals in early studies required 30-90 daily in- 
jections of IgG from patients with LEMS to pro- 
duce electrophysiologic changes.I5 Recent studies 
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suggest that a more rapid time course rnay 
occur." The IgG serum fraction derived from 
two of 25 patients with LEMS produced the elec- 
trophysiologic abnormalities of LEMS in mice af- 
ter a single injection. Within the first day there 
was a reduction in quantal release of acetylcholine 
which reached a plateau in 3-4 days. After 8 days 
recovery began, and quantal release returned to 
normal levels by 20-30 days. The transient nature 
of our patient's weakness is thus consistent with a 
short-lived rise in antibody titers. 
The clinical circumstances and course of our 
patient suggests a number of implications, The 
antigenic site on the presynaptic membrane in 
LEMS rnay be associated with calcium channels in 
the region of the active sites5 LEhfS may be ex- 
plained in part by antibody cross reactivity with 
these sites which may occur in some patients with 
other autoimmune diseases. It is not known if an- 
tibody cross reactivity with brain (central nervous 
system) tissue antigen in patients with SLE can be 
extended to include peripheral nervous system tis- 
sue. The incidence of neuromuscular disorders in 
SLE is unknown, but only one other association of 
SLE and LEMS has been reported, and that pa- 
tient had a long history of progressive weakness.' 
The restoration of clinically normal strength in 
our patient before the resolution of electrodiag- 
nostic abnormalities suggests that subclinical evi- 
dence of- LEMS may exist. 
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